Skip to content
Search

Latest Stories

Zydus Cadila gets USFDA nod for generic cancer drug

Zydus Cadila gets USFDA nod for generic cancer drug
Shilpa Sharma
By Shilpa SharmaJun 25, 2021
Shilpa Sharma
See Full Bio

DRUG maker Zydus Cadila today (25) received an approval from the US health regulator to market Pemetrexed injection in the American market.

Pemetrexed is used to treat certain kinds of cancers such as lung cancer, mesothelioma. It is a chemotherapy drug that helps in slowing or stopping the growth of cancer cells.

The firm got nod from the US Food and Drug Administration (USFDA) for the injection in the strengths of 100mg/vial, 500 mg/vial, and 1000 mg/vial, single-dose vials, it said in a statement.

The approved drug will be produced at the formulation manufacturing facility at Ahmedabad in India, the company said.

Zydus Cadila now has 319 approvals.

Since 2003-04, the company has filed over 400 abbreviated new drug applications (ANDAs).

The company discovers, develops, manufactures, and markets a broad range of healthcare products. The group employs around 25,000 people worldwide.

usindia

Related News

Sanjay Bhandari's extradition appeal opens in London
Business

Sanjay Bhandari's extradition appeal opens in London

Rupert Murdoch looks on as he walks on the day of the hearing on the contentious matter of succession of Rupert Murdoch's global television and publishing empire, in Reno, Nevada, US, September 23, 2024. (Photo: Reuters)
Business

Murdoch's bid to secure eldest son's control of media empire fails

Kamlesh Pattni faces UK sanctions for illicit gold trade
Business

Kamlesh Pattni faces UK sanctions for illicit gold trade

Sanjay Malhotra speaks during the 67th Foundation Day of the Directorate of Revenue Intelligence (DRI) in New Delhi on December 4, 2024. (Photo: Getty Images)
Business

India appoints Sanjay Malhotra as new central bank governor

EasternEye

More For You

aircraft

EasyJet announced it had already completed updates on many aircraft and planned to operate normally

Getty Images

Airbus grounds 6,000 aircraft over solar radiation risk

Highlights

  • Around 6,000 Airbus A320 family aircraft grounded worldwide, affecting half the manufacturer's global fleet.
  • Issue discovered following October incident where JetBlue flight experienced sudden altitude loss, injuring 15 passengers.
  • Most aircraft require three-hour software update, but 900 older planes need complete computer replacement.
Thousands of Airbus planes have been grounded globally after the European aerospace manufacturer discovered that intense solar radiation could interfere with critical flight control computers.
The revelation has triggered widespread flight cancellations and delays, particularly affecting the busy US Thanksgiving travel weekend.

The vulnerability impacts approximately 6,000 aircraft from the A320 family, including the A318, A319, and A321 models. Airbus identified the problem while investigating an October incident where a JetBlue Airways flight travelling between Mexico and the US made an emergency landing in Florida after experiencing a sudden drop in altitude.

The issue relates to computing software that calculates aircraft elevation. Airbus found that intense radiation periodically released by the sun could corrupt data at high altitudes in the ELAC computer, which operates control surfaces on the wings and horizontal stabiliser

Keep ReadingShow less
© Copyright 2025 Garavi Gujarat Publications Ltd & Asian Media Group USA Inc
Contact Us